Krystal Biotech receives approval in Europe for gene therapy treatment
A gene therapy company has received a designation for one of its treatments from the European Medicines Agency.
Krystal Biotech, developing and commercializing novel treatments for dermatological diseases, announced that KB103, a treatment for a severe skin disorder, was granted an Orphan Medicinal Product Designation by the agency, according to a news release.
In November 2017, the FDA granted the same de signation for the treatment, which is meant for dystrophic epidermolysis bullosa, an incurable…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Stacey Federoff Source Type: news
More News: Biotechnology | Dermatology | Epidermolysis Bullosa | European Medicines Agency (EMA) | Gene Therapy | Genetics | Health Management | Skin